Cancer chemotherapeutics in rheumatoid arthritis: A convoluted connection

Shanker, Jayashree; Nirekshana, K.; Guha, Gunjan; Bhakta-Guha, Dipita

doi:10.1016/j.biopha.2018.03.123

Cited by 14 publications

(14 citation statements)

References 337 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, various non-pharmacological and pharmacological approaches, including recognition and avoidance of causative factors, non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressant therapies, herbal therapies (plant extract, oils), and physical measures (physiotherapy), have been used, either alone or in combination for the management of acute to chronic RA. The initial phase of RA can potentially be treated with NSAIDs; however, the chronic phase requires intensive therapies of disease modifying antirheumatic drugs (DMARDs), including modern biologics [ 31 ]. DMARDs such as methotrexate, leflunomide, sulfasalazine, and mycophenolate, etc., and modern biologics that specifically target cytokines and inflammation-inducing cells are used to ameliorate pain and prevent bone damage [ 31 ].…”

Section: Rheumatoid Arthritismentioning

confidence: 99%

“…The initial phase of RA can potentially be treated with NSAIDs; however, the chronic phase requires intensive therapies of disease modifying antirheumatic drugs (DMARDs), including modern biologics [ 31 ]. DMARDs such as methotrexate, leflunomide, sulfasalazine, and mycophenolate, etc., and modern biologics that specifically target cytokines and inflammation-inducing cells are used to ameliorate pain and prevent bone damage [ 31 ]. Besides their potential application in RA, DMARDs and biologics are also associated with numerous side effects such as TNF-α inhibition, which is associated with the risk of tuberculosis [ 32 ]; and tocilizumab, which is associated with a risk of lower intestinal perforation [ 33 ].…”

Section: Rheumatoid Arthritismentioning

confidence: 99%

“…Besides their potential application in RA, DMARDs and biologics are also associated with numerous side effects such as TNF-α inhibition, which is associated with the risk of tuberculosis [ 32 ]; and tocilizumab, which is associated with a risk of lower intestinal perforation [ 33 ]. A large number of patients are resistant to current drugs with only 20–30% reaching low disease activity status and none of them can completely cure RA [ 31 ].…”

Section: Rheumatoid Arthritismentioning

confidence: 99%

See 2 more Smart Citations

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

Cancer causes a considerable amount of mortality in the world, while arthritis is an immunological dysregulation with multifactorial pathogenesis including genetic and environmental defects. Both conditions have inflammation as a part of their pathogenesis. Resistance to anticancer and disease-modifying antirheumatic drugs (DMARDs) happens frequently through the generation of energy-dependent transporters, which lead to the expulsion of cellular drug contents. Thymoquinone (TQ) is a bioactive molecule with anticancer as well as anti-inflammatory activities via the downregulation of several chemokines and cytokines. Nevertheless, the pharmacological importance and therapeutic feasibility of thymoquinone are underutilized due to intrinsic pharmacokinetics, including short half-life, inadequate biological stability, poor aqueous solubility, and low bioavailability. Owing to these pharmacokinetic limitations of TQ, nanoformulations have gained remarkable attention in recent years. Therefore, this compilation intends to critically analyze recent advancements in rheumatoid arthritis and cancer delivery of TQ. This literature search revealed that nanocarriers exhibit potential results in achieving targetability, maximizing drug internalization, as well as enhancing the anti-inflammatory and anticancer efficacy of TQ. Additionally, TQ-NPs (thymoquinone nanoparticles) as a therapeutic payload modulated autophagy as well as enhanced the potential of other drugs when given in combination. Moreover, nanoformulations improved pharmacokinetics, drug deposition, using EPR (enhanced permeability and retention) and receptor-mediated delivery, and enhanced anti-inflammatory and anticancer properties. TQ’s potential to reduce metal toxicity, its clinical trials and patents have also been discussed.

show abstract

Section: Rheumatoid Arthritismentioning

confidence: 99%

Section: Rheumatoid Arthritismentioning

confidence: 99%

Section: Rheumatoid Arthritismentioning

confidence: 99%

See 1 more Smart Citation

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Rheumatoid arthritis (RA) which is a chronic autoimmune disease affecting the joints has transpired into a discernible concern affecting the global health since decades [1,2] . Dorothy Hodgkin who was a pioneer in X‐ray crystallography and was awarded in 1964 with Nobel Prize in chemistry had crippled hands and feet due to lifelong RA.…”

Section: Introductionmentioning

confidence: 99%

Trace Level Recognition of Sulfasalazine Electrooxidation Exploiting the Synergism of Carbon Nanotubes and Iron Oxide Nanoparticles

Mane

Chatterjee

2021

ChemistrySelect

View full text Add to dashboard Cite

The significance of sulfasalazine (SSZ) as a therapeutic agent has garnered paramount research interest in the design and fabrication of a viable sensor for the detection of SSZ. Herein, we demonstrate a new strategy for the sensitive determination of SSZ employing single walled carbon nanotubes decorated with Fe3O4 nanoparticles sensing platform for the first time. The synthesized Fe3O4 nanoparticles and the surface morphology of the developed sensor were investigated by exerting various analytical techniques. The optimization of operational parameters was effectuated. The developed sensor exhibited pronounced electrocatalytic activity for the electro oxidation of SSZ in the dynamic detection range of 25 nM–1.5 μM manifesting noteworthy high sensitivity and phenomenal low detection limit of 18.6 μA μM−1 and 1.6 nM respectively. Apparent specificity in the presence of interferents along with remarkable stability and reproducibility were attained by the sensor. The prominence of the developed methodology was emphasized by the determination of SSZ in pharmaceutical formulations. Furthermore, the applicability of the developed electrode was established by utilizing it effectually for the first time to quantify SSZ in serum sample of patients undergoing pharmacological treatment for rheumatoid arthritis.

show abstract

“…Rheumatoid arthritis death related to cardiac diseases and complications associated with pulmonary is 10-20% and 60-80% [3]. Currently, patients with rheumatoid arthritis have parallel occurrences associated with an increased risk rate of cancer during therapy or after the therapy [4]. During the 1970s, rheumatoid arthritis was detected by analyzing the synovial fluid of the patients and the elevated intensities of prostaglandins were identified.…”

Section: Introductionmentioning

confidence: 99%

A Comprehensive Review on Rheumatoid Arthritis

Nithyashree

Deveswaran

2020

JPRI

View full text Add to dashboard Cite

Rheumatoid arthritis is an enduring inflammatory disease that is categorized by bumping off the joint and rigidity, bone and cartilage devastation all above the joints. It is an autoimmune disease or disease caused by factors like smoking, obesity, etc. Cytokines are the main inducers for rheumatoid arthritis which produce interleukin 1β and interleukin 6 factors that cause the devastation of synovium and cartilage present at the joints. The deformation of skeletal muscles is observed in an arthritic patient. The present review is a discussion on rheumatoid arthritis that includes etiology, pathology and pathogenesis, signs and symptoms, clinical complications, diagnosis, treatment, therapy, certain patents and applications. The patents include the development of numerous novel techniques for the management of rheumatoid arthritis and diseases associated with rheumatoid arthritis. The targets to treat rheumatoid arthritis are interleukins, tumor necrosis factor-alpha, sialoprotein I and several other factors. Different biomarkers are used for different types of rheumatoid arthritis and the mechanism also varies. Certain marketed formulations were enlisted. Recent trends in the management of rheumatoid arthritis are the main concern of this article.

show abstract

Cancer chemotherapeutics in rheumatoid arthritis: A convoluted connection

Cited by 14 publications

References 337 publications

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

Trace Level Recognition of Sulfasalazine Electrooxidation Exploiting the Synergism of Carbon Nanotubes and Iron Oxide Nanoparticles

A Comprehensive Review on Rheumatoid Arthritis

Contact Info

Product

Resources

About